Special Session: Gene TherapyBioethical Analysis of Stakeholders’ Perspectives About Gene Therapy for Hearing Loss In conclusion of this panel discussion before opening for discussion with the attendees, Ms. Kagel will shift gears from the patient perspective to provide a real-time bioethical analysis of the various stakeholders’ perspectives on gene therapy for hearing loss. In this setting, Ms. Kagel will real-time identify and respond to the various bioethical tensions based on the presentations made by various stakeholders on the panel. Emphasis will be placed on which bioethical principles can be utilized and how they assist stakeholders in navigating the real value conflicts that do and will exist as part of developing and offering gene therapy for hearing loss in research and clinical practice.
Emma J. Kagel, JD, MBE, HCE-C, LPEC is an affiliate of the Center for Bioethics at Harvard Medical School and manages the Conflict of Interest program for the Beth Israel Lahey Health health system. Ms. Kagel received her JD from the University of Washington School of Law and her MBE in Bioethics from Harvard Medical School. She is a certified healthcare ethics consultant by the American Society of Bioethics and Humanities having spent over a two decades at the bedside in clinical consultations and overseeing clinical ethics programs before transitioning to research bioethics practice. She has also been involved in the Medical Legal Partnership space in healthcare systems to utilize legal levers to improve the social determinants of health. Ms. Kagel identifies as deaf with cochlear implants. Her personal and professional knowledge has informed her efforts in disability advocacy in healthcare, education, and legal settings.
|
